Protein kinase inhibitors as targeted therapy for glioblastoma: a meta-analysis of randomized controlled clinical trials
Glioblastoma (GBM) is the most common and lethal primary brain tumor. The standard treatment for newly diagnosed GBM includes surgical resection, when feasible, followed by radiotherapy and temozolomide-based chemotherapy. Upon disease progression, the anti-vascular endothelial growth factor-A (VEGF...
Saved in:
Main Authors: | José Pinto-Fraga, Celia García-Chico, Simone Lista, Pedro Miguel Lacal, Giuseppe Carpenzano, Maurizio Salvati, Alejandro Santos-Lozano, Grazia Graziani, Claudia Ceci |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2025-02-01
|
Series: | Pharmacological Research |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1043661824004730 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Vascular Endothelial Growth Factor (VEGF) Family and the Immune System: Activators or Inhibitors?
by: Cristina Maria Failla, et al.
Published: (2024-12-01) -
Did selective kinase inhibitors change the management of patients with radioiodine-refractory thyroid cancer?
by: Tommaso Porcelli, et al.
Published: (2025-02-01) -
The tyrosine kinase inhibitor lenvatinib is oxidized by rat cytochromes P450 and affects their expression in rat liver
by: Indra Radek, et al.
Published: (2024-09-01) -
Magnetic and pH sensitive nanocomposite microspheres for controlled temozolomide delivery in glioblastoma cells
by: Meysam Ahmadi, et al.
Published: (2024-12-01) -
Associated adverse outcomes with tumor treating fields when combined to temozolomide versus temozolomide alone for the treatment of glioblastoma: a meta-analysis of randomized trials
by: Yuanyuan Chen, et al.
Published: (2025-02-01)